Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 10 systematic review(s)/meta-analysis(es). ^[1-10]
• Tenofovir-based therapies for HIV prevention and treatment are associated with common neuropsychiatric adverse events (NPAEs), including headache, dizziness, insomnia, and depression. Tenofovir alafenamide specifically showed a higher risk of headache in HIV studies (OR (odds ratio) 1.24, CI (confidence interval) 1.01-1.52).
• Oral PrEP was effective in HIV prevention for men who have sex with men (MSM), serodiscordant couples, and people who inject drugs (PWID), but not effective in heterosexual populations. The effectiveness of PrEP was closely associated with adherence levels.
• In comparison to tenofovir disoproxil fumarate-emtricitabine, long-acting cabotegravir (CAB-LA) was more effective in preventing HIV (RR (relative risk) 0.21, CI 0.07-0.61) and showed sustained virological suppression when combined with rilpivirine (RPV-LA) over extended periods.
• In ART (antiretroviral therapy)-naive people with HIV, dolutegravir plus lamivudine (DTG+3TC) demonstrated similar efficacy but fewer serious adverse events compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC).
• NPAEs associated with tenofovir-based therapies included headache, dizziness, insomnia, and depression, with an increased risk of dizziness noted (OR 1.32; CI 1.09-1.59; P = 0.004). A higher risk of headache was observed with tenofovir alafenamide in HIV studies (OR 1.24; CI 1.01-1.52; P = 0.04).
• Safety outcomes from long-acting cabotegravir (CAB-LA) and rilpivirine (RPV-LA) showed comparable safety profiles to placebo, though CAB-LA+RPV-LA was associated with more mild to moderate injection site reactions.
• Dolutegravir plus lamivudine (DTG+3TC) resulted in fewer serious adverse events compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/abacavir/lamivudine (DTG/ABC/3TC).
• The population types studied included treatment-naive adults using tenofovir-based therapies, pregnant women in Africa assessed for adverse perinatal outcomes related to PrEP, and people living with HIV evaluated for long-acting antiretrovirals (ARVs) and daily oral drug regimens. Findings indicated that tenofovir-based therapies commonly led to neuropsychiatric adverse events such as headache, dizziness, insomnia, and depression, and that oral PrEP was not associated with adverse perinatal outcomes like preterm birth or low birth weight.